Intellipharmaceutics International Inc. (IPCIF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Intellipharmaceutics International Inc. (IPCIF) with AI Score 54/100 (Hold). Intellipharmaceutics International Inc. is a pharmaceutical company focused on researching, developing, and manufacturing controlled-release and targeted-release oral solid dosage drugs. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 15, 2026Intellipharmaceutics International Inc. (IPCIF) Healthcare & Pipeline Overview
Intellipharmaceutics International Inc. develops and manufactures novel and generic controlled-release drugs, leveraging its Hypermatrix technology across therapeutic areas like neurology, cardiovascular, and diabetes. The company's portfolio includes extended-release versions of established drugs, positioning it within the competitive biotechnology sector focused on drug delivery systems.
Investment Thesis
Intellipharmaceutics International Inc. presents a focused investment opportunity within the biotechnology sector, driven by its proprietary Hypermatrix technology for controlled-release drug formulations. The company's strategy of developing generic versions of established drugs, such as Focalin XR and Keppra XR, provides a pathway to revenue generation. Key value drivers include the successful development and commercialization of its pipeline products, particularly OxyContin and Regabatin XR. The company's gross margin of 100.0% indicates strong potential profitability if sales volume increases. However, the company's negative profit margin of -4400.6% and small market capitalization of $0.00B highlight the risks associated with investing in a small, development-stage pharmaceutical company. Upcoming catalysts include potential regulatory approvals for pipeline drugs and expansion of its commercial partnerships. Investors should carefully consider the risks associated with OTC-listed companies and the company's financial performance.
Based on FMP financials and quantitative analysis
Key Highlights
- Intellipharmaceutics International Inc. operates with a small team of 11 employees, indicating a lean operational structure.
- The company boasts a 100.0% gross margin, suggesting efficient production and pricing strategies.
- The company has a negative P/E ratio of -1.72, reflecting current losses but potential for future earnings.
- The company's beta of 0.40 suggests lower volatility compared to the broader market.
- The company's pipeline focuses on extended-release formulations, potentially offering improved patient compliance and market differentiation.
Competitors & Peers
Strengths
- Patented Hypermatrix technology
- Focus on controlled-release drug formulations
- Established partnerships with pharmaceutical companies
- Expertise in developing generic drugs
Weaknesses
- Small market capitalization
- Negative profit margin
- Limited financial resources
- Dependence on regulatory approvals
Catalysts
- Upcoming: Potential regulatory approvals for pipeline drugs, such as OxyContin and Regabatin XR.
- Ongoing: Expansion of commercial partnerships with pharmaceutical companies.
- Ongoing: Continued research and development of novel drug delivery systems.
- Ongoing: Market growth in controlled-release drug formulations.
- Ongoing: Strategic focus on high-value therapeutic areas.
Risks
- Potential: Competition from larger pharmaceutical companies with greater resources.
- Potential: Patent expiration and generic competition for existing products.
- Potential: Regulatory hurdles and delays in drug approval processes.
- Ongoing: Dependence on a limited number of products and partnerships.
- Ongoing: Financial losses and need for additional funding.
Growth Opportunities
- Expansion of Product Pipeline: Intellipharmaceutics has the opportunity to expand its product pipeline by developing new controlled-release formulations of existing drugs. The market for generic drugs is substantial, with a global market size estimated at $460 billion in 2024. By leveraging its Hypermatrix technology, Intellipharmaceutics can create differentiated products with improved therapeutic profiles, potentially capturing a significant share of this market. The timeline for this growth opportunity is ongoing, with continuous research and development efforts.
- Strategic Partnerships and Licensing Agreements: The company can pursue strategic partnerships and licensing agreements with larger pharmaceutical companies to commercialize its products in new markets. Licensing agreements can provide Intellipharmaceutics with upfront payments, milestone payments, and royalties on sales, generating revenue without requiring significant investment in sales and marketing infrastructure. This strategy can accelerate the company's growth and expand its geographic reach. The timeline for this growth opportunity is within the next 1-3 years.
- Focus on High-Value Therapeutic Areas: Intellipharmaceutics can focus its research and development efforts on high-value therapeutic areas, such as neurology and pain management, where there is a significant unmet medical need and a growing market for innovative drug formulations. The global pain management market is projected to reach $91.5 billion by 2028. By developing effective and safe pain management drugs, Intellipharmaceutics can address a critical healthcare need and generate substantial revenue. The timeline for this growth opportunity is within the next 3-5 years.
- Leveraging Hypermatrix Technology: Intellipharmaceutics can further leverage its patented Hypermatrix technology to develop novel drug delivery systems for a wider range of therapeutic applications. This technology can be applied to create controlled-release formulations of biologics and other complex molecules, opening up new market opportunities. The company can also explore the use of Hypermatrix technology to develop targeted drug delivery systems that deliver drugs directly to the site of action, minimizing side effects and improving therapeutic efficacy. The timeline for this growth opportunity is ongoing, with continuous innovation and development.
- Capitalizing on Regulatory Pathways: Intellipharmaceutics can capitalize on regulatory pathways, such as the 505(b)(2) pathway in the United States, to accelerate the approval of its generic drug products. The 505(b)(2) pathway allows companies to rely on existing safety and efficacy data for previously approved drugs, reducing the time and cost required to bring new products to market. By strategically utilizing this pathway, Intellipharmaceutics can gain a competitive advantage and bring its products to market more quickly. The timeline for this growth opportunity is within the next 1-2 years.
Opportunities
- Expansion of product pipeline
- Strategic partnerships and licensing agreements
- Focus on high-value therapeutic areas
- Leveraging Hypermatrix technology for new applications
Threats
- Competition from larger pharmaceutical companies
- Patent expiration and generic competition
- Regulatory hurdles and delays
- Product liability claims
Competitive Advantages
- Patented Hypermatrix technology provides a competitive advantage in drug delivery.
- Focus on controlled-release formulations offers improved patient compliance and therapeutic efficacy.
- Strategic partnerships with established pharmaceutical companies enhance market access.
- Expertise in developing generic versions of established drugs reduces development costs and time.
About IPCIF
Founded in 1998 and based in Toronto, Canada, Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development, and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. The company's core strength lies in its patented Hypermatrix technology, which forms the foundation for its drug delivery systems and product pipeline. These products target a range of therapeutic areas, including neurology, cardiovascular health, the gastrointestinal tract, diabetes, and pain management. Intellipharmaceutics offers extended-release versions of established drugs, such as Focalin XR for hyperactivity disorder, Keppra XR for epilepsy, Effexor XR for depression, and Protonix for gastroesophageal reflux disease. Other products include Glucophage XR for type 2 diabetes, Seroquel XR for schizophrenia and bipolar disorder, Lamictal XR for epilepsy, Pristiq for depression, Coreg CR for heart failure and hypertension, and Ranexa for chronic angina. The company is also developing OxyContin for pain management and Regabatin XR for neuropathic pain. Intellipharmaceutics has a license and commercialization agreement with Par Pharmaceutical Inc., demonstrating its ability to partner for wider market access.
What They Do
- Researches and develops novel drug delivery systems.
- Manufactures controlled-release and targeted-release oral solid dosage drugs.
- Utilizes patented Hypermatrix technology for drug formulation.
- Develops generic versions of established drugs.
- Focuses on therapeutic areas including neurology, cardiovascular, and diabetes.
- Seeks regulatory approvals for its drug products.
- Partners with other pharmaceutical companies for commercialization.
Business Model
- Develops and manufactures generic and novel controlled-release drugs.
- Generates revenue through product sales.
- Out-licenses its technology and products to other pharmaceutical companies.
- Pursues strategic partnerships for commercialization and distribution.
Industry Context
Intellipharmaceutics International Inc. operates within the biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The market for controlled-release drug formulations is growing, driven by the demand for improved drug efficacy, reduced side effects, and enhanced patient convenience. Intellipharmaceutics competes with both large pharmaceutical companies and smaller biotech firms in developing and commercializing its products. The company's success depends on its ability to innovate, secure regulatory approvals, and establish strategic partnerships.
Key Customers
- Patients who require medication for various therapeutic areas.
- Pharmacies that dispense the company's drugs.
- Hospitals and clinics that use the company's products.
- Pharmaceutical companies that license the company's technology.
Financials
Chart & Info
Intellipharmaceutics International Inc. (IPCIF) stock price: Price data unavailable
Latest News
-
Reviewing Intellipharmaceutics International (OTCMKTS:IPCIF) & Neoleukin Therapeutics (NASDAQ:NLTX)
defenseworld.net · Feb 1, 2026
-
Stocks That Hit 52-Week Highs On Friday
· Dec 13, 2019
-
Stocks That Hit 52-Week Lows On Monday
· Oct 21, 2019
-
Stocks That Hit 52-Week Lows On Thursday
· Oct 17, 2019
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for IPCIF.
Price Targets
Wall Street price target analysis for IPCIF.
MoonshotScore
What does this score mean?
The MoonshotScore rates IPCIF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Reviewing Intellipharmaceutics International (OTCMKTS:IPCIF) & Neoleukin Therapeutics (NASDAQ:NLTX)
Stocks That Hit 52-Week Highs On Friday
Stocks That Hit 52-Week Lows On Monday
Stocks That Hit 52-Week Lows On Thursday
Leadership: Isa Odidi MBA,
CEO
Isa Odidi is the CEO of Intellipharmaceutics International Inc. He possesses an MBA, indicating a strong foundation in business administration and management. His background likely includes experience in the pharmaceutical industry, with a focus on strategic planning, product development, and commercialization. His leadership is crucial for guiding the company's growth and navigating the complexities of the biotechnology sector.
Track Record: Under Isa Odidi's leadership, Intellipharmaceutics International Inc. has focused on developing and commercializing controlled-release drug formulations. Key achievements include securing partnerships for product commercialization and advancing the company's pipeline of generic drug products. His strategic decisions have been instrumental in positioning the company within the competitive biotechnology landscape.
IPCIF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, encompassing stocks that may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited or no financial disclosure, making it difficult for investors to assess their financial health and operational performance. Investing in OTC Other stocks carries significant risks due to the lack of transparency and regulatory oversight compared to stocks listed on major exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure
- Low liquidity and wide bid-ask spreads
- Potential for price manipulation
- Lack of regulatory oversight
- Higher risk of fraud and scams
- Verify the company's registration and regulatory filings.
- Review the company's financial statements, if available.
- Assess the company's management team and their experience.
- Research the company's products and services.
- Evaluate the company's competitive position.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor.
- Company has been in operation for an extended period.
- Company possesses patents or other intellectual property.
- Company has established partnerships with reputable organizations.
- Company has a functional website and contact information.
- CEO has an MBA
What Investors Ask About Intellipharmaceutics International Inc. (IPCIF)
What does Intellipharmaceutics International Inc. do?
Intellipharmaceutics International Inc. is a pharmaceutical company that researches, develops, and manufactures controlled-release and targeted-release oral solid dosage drugs. The company's core technology is its patented Hypermatrix platform, which enables the creation of extended-release formulations for both novel and generic drugs. These formulations are designed to improve drug efficacy, reduce side effects, and enhance patient compliance. Intellipharmaceutics focuses on therapeutic areas such as neurology, cardiovascular health, diabetes, and pain management, offering products like Focalin XR, Keppra XR, and Glucophage XR. The company also seeks partnerships to commercialize its products and expand its market reach.
What do analysts say about IPCIF stock?
Given the lack of recent analyst coverage and the company's OTC listing, there is no readily available analyst consensus for IPCIF stock. Investors should conduct their own thorough due diligence, considering the company's financial performance, pipeline progress, and competitive landscape. Key valuation metrics, such as price-to-sales and price-to-book ratios, may be difficult to interpret due to the company's current financial losses. Growth considerations include the successful development and commercialization of pipeline products and the expansion of strategic partnerships. It is important to note the risks associated with investing in OTC-listed companies, including limited liquidity and regulatory oversight.
What are the main risks for IPCIF?
Intellipharmaceutics International Inc. faces several key risks, including competition from larger pharmaceutical companies with greater resources, patent expiration and generic competition for its existing products, and regulatory hurdles and delays in drug approval processes. The company's small market capitalization and negative profit margin also pose financial risks, as it may need to raise additional capital to fund its operations. Furthermore, the company's dependence on a limited number of products and partnerships makes it vulnerable to changes in market demand and competitive dynamics. Investing in IPCIF carries the risks associated with OTC-listed companies, including limited liquidity and regulatory oversight.
What are the key factors to evaluate for IPCIF?
Intellipharmaceutics International Inc. (IPCIF) currently holds an AI score of 54/100, indicating moderate score. Key strength: Patented Hypermatrix technology. Primary risk to monitor: Potential: Competition from larger pharmaceutical companies with greater resources.. This is not financial advice.
How frequently does IPCIF data refresh on this page?
IPCIF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven IPCIF's recent stock price performance?
Recent price movement in Intellipharmaceutics International Inc. (IPCIF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Patented Hypermatrix technology. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider IPCIF overvalued or undervalued right now?
Determining whether Intellipharmaceutics International Inc. (IPCIF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying IPCIF?
Before investing in Intellipharmaceutics International Inc. (IPCIF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is limited and may not be fully up-to-date.
- Analyst coverage is scarce, requiring independent due diligence.
- OTC listing introduces additional risks related to liquidity and transparency.